However, the characteristics of participants in the study and control groups were different, with a higher clinical stage, a higher incidence of lymph node positive, and a higher incidence of HER2 positive or triple negative breast cancer in the study group. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.